20433 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
COMPOSITIONS COMPRISING BETA-ADRENERGIC RECEPTOR ANTAGONISTS AND DIURETICS
#302Combination of brimonidine and timolol for topical ophthalmic use
#303Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors
#304Compositions including antibiotics and methods for using same
#305Antifungal compositions and method
#306Treatment For Alzheimer's Disease And Related Conditions
#307Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
#308Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with FR type receptors
#309Anti-inflammatory medicaments
#310Anti-inflammatory medicaments
#311Arylpyrazoles And Methods Of Using Same For Control Of Insect Pests That Bore Into Trees
#312Compounds for the treatment of metabolic disorders
#313ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
#314Compounds for the treatment of metabolic disorders
#315COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
#316HIV integrase inhibitors
#317COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
#318Method for the treatment of metabolic disorders
#319Method of Adenovirus, HIV and HPV Prophylaxis
#320Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
#321COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
#322COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
#323Pyrazoloquinolones are potent PARP inhibitors
#324Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
#325Use of nitric oxide adducts
#326Pharmaceutical compositions and uses thereof
#327Method for the treatment of metabolic disorders
#328COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
#329COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
#330BRIMONIDINE AND TIMOLOL COMPOSITIONS
#331Alkoxyphenylpropanoic acid derivatives
#332Pharmaceutical composition
#333Production of tacrolimus (fk-506) using new streptomyces species
#334Cancer treatment method
#335Medicaments for the treatment of chronic obstructive pulmonary disease
#336Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury
#337Uses of rifamycins
#338Substituted furo[2,3-g]indazoles for the treatment of glaucoma
#339Aminosulfonic acid compounds for promoting desquamation of the skin
#340INDOLE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER
#341Methods for the treatment of metabolic disorders such as diabetes
#342Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
#343Unitary pharmaceutical dosage form
#344Method and composition for pharmaceutical product
#345Method for treating peripheral neuropathic pain
#346Immunosuppresive effects of pteridine derivatives
#347Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments
#348Methods and composition for inhibition of angiogenesis
#349Supramolecular complexes as photocatalysts for the production of hydrogen from water
#350Extended release formulations
#351Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
#352Inhibitors of FtsZ and uses thereof
#353Combination therapy for effecting weight loss and treating obesity
#354Combination therapy for effecting weight loss and treating obesity
#355Combination therapy for effecting weight loss and treating obesity
#356Compressed tablet formulation
#357Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
#358Functionalized drugs and polymers derived therefrom
#359Microbicidal pyrimidine or triazine for preventing sexual HIV transmission
#360Crystalline form IV of linezolid
#361Cosmetic and pharmaceutical foam
#362Supramolecular complexes as photocatylysts for the production of hydrogen from water
#363New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease
#364Pin1-Modulating compounds and methods of use thereof
#365Pi3k antagonists as radiosensitizers
#366Combination therapy for treating viral infections
#367Combination of formoterol and a tiotropium salt
#368N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors
#369Intermediates of bupropion metabolites synthesis
#370Compounds
#371Diketopiperazine salts for drug delivery and related methods
#372SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
#373Composition for topical administration
#374Methods for treating or preventing erectile dysfunction or urinary incontinence
#375New drug combinations
#376Body cavity foams
#377Compounds which inhibit leukocyte adhesion mediated by VLA-4
#378Combination cancer therapy
#379Compounds for the treatment of metabolic disorders
#380Novel compounds
#381Method and composition for rejuvinating cells, tissues organs, hair and nails
#382Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
#383Medicaments for the treatment of chronic obstructive pulmonary disease
#384Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide
#385Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
#386Methods for treating pain
#387Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
#388Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
#389Method for modulating calcium ion-release-activated calcium ion channels
#390Targeted oxidative therapeutic formulation
#391Targeted oxidative therapeutic formulation
#392Pharmaceutical compositions based on anticholinergics and additional active ingredients
#393Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
#3943-Substituted-4-pyrimidone derivatives
#395Methods of treating alzheimer's disease
#396Transcription factor modulating compounds and methods of use thereof
#397Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
#398Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury
#399Compounds for inflammation and immune-related uses
#400Cell line comprising vector encoding truncated FLK-1 receptor
#401Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
#402Compound for the treatment of metabolic disorders
#403Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
#404Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
#405Methods and compositions for the treatment of eye diseases
#406Pharmaceutical composition comprising n((1-n-butyl-4-piperidinyl)methyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process therefor comprising dry granulation
#407Dermatological compositions and methods
#408Multi-system therapy for diabetes, the metabolic syndrome and obesity
#409Pharmaceutical composition
#410GSK-3 inhibitors
#411Personalized cosmetics
#412Combined agents for treatment of glaucoma
#413Medicaments for inhalation comprising a novel anticholinergic and a steroid
#414Partial dopamine-D 2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
#415Method for treating fibrotic diseases or other indications utilizing thiazole, oxazole and imidazole compounds
#416Pharmaceutical preparations comprising substituted beta-aminoalcohols
#417Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
#418Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
#419Combined agents for treatment of glaucoma
#420Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
#421Compounds for the treatment of metabolic disorders
#422Methods and compositions for treating an ocular neovascular disease